[Effect of irbesartan--angiotensin II type I receptor inhibitor on oxidative metabolism of lipids in essential hypertension].

We evaluated the alters in plasma vasoconstriction eicosanoids (LTC4, TXB2) and diene conjugates (DC) levels in patients with essential hypertension (EH) after chronic (30 days, 235 mg per day) of irbezartane (inhibitor of ANG II type 1 receptor with prolongation action "Aprovel" from "Sanofi") oral administration. Patients with EH have significantly higher plasma both LTC4, TXB2 and DC levels then healthy controls. This imbalance can be beneficially modulated by chronic irbezartane ("Aprovel") administration.

[Increased level of nitric oxide stable metabolites in the blood of highlanders].

The investigation was designed to study nitric oxide (NO) blood level estimated by measuring its stable metabolites nitrite (NO2-) and nitrate (NO3-) concentration in highlanders (2,200 m a.s.l.

[Effect of irbesartan, an antagonist of AT-1 receptors for angiotensin II, on L-arginine metabolism in arterial hypertension].

Effects of an antagonist of AT-1 receptors for angiotensin-II (Ang-II) irbezantane on the NO-synthase and arginase ways of the metabolism of L-arginine were studied in plasma and erythrocytes of the patients with arterial hypertension. The intensity of the non-oxidative arginase way of L-arginine metabolism in plasma and erythrocytes has been shown to be inhanced at hypertension versus the normotensive patients, while the activity of the alternative oxidative NO-synthase way was reduced. Inhibiting AT-1 receptors for Ang-II with high-affinity antagonist irbezantane normalized the ratio between two alternative ways of L-arginine metabolism through inhibiting the arginase way and reciprocal activating the NO-synthase way both in human plasma and erythrocytes.

[A chronic hyperimmunocomplex process and its interrelationship with free radical-generating systems].

On chronic hyperimmunocomplex process (CHIP) model in rats of Wistar line (Cochrane C., Koffen D., 1973) we determined cAMP and cGMP concentration, nitrogen oxide (NO), urine, urine acid,--in muscle and clearance organs, and also in plasma.

[The C(27)-steroid hormones ecdysterone and calcitriol activate the phosphoinositol cycle in its membrane phase].

We have examined in vivo the capacities of two C27-steroid hormones-phytoecdysteroid ecdysterone (20-hydroxyecdysone, 10(-8) M) and calcitriol (1 alpha, 25-dihydroxyvitamin D3, 10(-12) M), as a modulators of phosphoinositide cycle in the brain and heart cells. Severe lines of evidence indicate that both hormones may acts as positive regulators of phosphoinositide hydrolysis by phospholipases C and D in membrane (0.5-30 min) pre-genomic phase of its actions.